(Q22241420)

Dimensions Publication ID

Dimensions

6 February 2023

Peter A. Calabresi

2

Peter A.

Calabresi

1 reference

Dimensions Publication ID

Dimensions

1018862288

https://scigraph.springernature.com/pub.10.2165/11596970-000000000-00000

6 February 2023

language of work or name

English

0 references

publication date

March 2012

0 references

published in

CNS Drugs

0 references

volume

26

0 references

issue

3

0 references

page(s)

205-214

0 references

exact match

0 references

cites work

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

PEGylation: an approach for drug delivery. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

21 January 2018

Emerging PEGylated drugs

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

PEG conjugates in clinical development or use as anticancer agents: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

PEGylation of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Pegylation: a novel process for modifying pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Preparation and characterization of mono-PEGylated epidermal growth factor: evaluation of in vitro biologic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Certolizumab pegol in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Demonstration of in vivo stability and lack of immunogenicity of a polyethyleneglycol-conjugated recombinant CHO-derived butyrylcholinesterase bioscavenger using a homologous macaque model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Pegylated IFNs for chronic hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Interferon therapy in patients with chronic hepatitis C and schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Novel erythropoiesis-stimulating agents: a new era in anemia management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

PEG-interferon in acute and chronic hepatitis C: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Advances in PEGylation of important biotech molecules: delivery aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

21 January 2018

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.

1 reference

12 December 2020

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

12 December 2020

PEGylation for improving the effectiveness of therapeutic biomolecules.

1 reference

12 December 2020

Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States

1 reference

12 December 2020

Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients.

1 reference

12 December 2020

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy

1 reference

12 December 2020

Obstacles and pitfalls in the PEGylation of therapeutic proteins.

1 reference

12 December 2020

PEG-modified biopharmaceuticals

1 reference

12 December 2020

Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States

1 reference

12 December 2020

Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity

1 reference

12 December 2020

Effect of the prokinetic agent, erythromycin, in the Richardson ground squirrel model of cholesterol gallstone disease

1 reference

https://api.crossref.org/works/10.2165%2F11596970-000000000-00000

7 January 2021